Olaparib
Auto-discovered · not yet curatedolaparib
Educational only, not medical advice. OncoForge makes no claim that Olaparib treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 3 recent studies; not yet curated.
Research
No published studies for Olaparib yet
New studies appear here once they’ve been reviewed. Browse all studies.
Trials studying Olaparib
107 recruiting on ClinicalTrials.gov. Recruiting is not the same as proven. Search ClinicalTrials.gov →
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)NCT06797635Phase 2Recruiting
- Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerNCT06686030Phase 2Recruiting
- Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)NCT06441747Phase 2Recruiting
- WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCNCT04644289Phase 2Recruiting
- Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian CancerNCT06572735Recruiting
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.